Finance

Lists
SGRY:NASDAQ
Surgery Partners Inc
USD 15,40
-0,58%
(-0,090) 1D
USD 15,40
0,00% (0,00)
After hours
Closed: 21 Okt., 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGRY...
Open
USD 15,19
High
USD 15,64
Low
USD 15,07
Mkt. cap
2,02 mjd
Avg. vol.
2,10 m
Volume
2,36 m
52-wk high
USD 23,44
52-wk low
USD 11,41
EPS
-USD 0,69
Beta
1,91
Shares outstanding
130,92 m
No. of employees
16 k
Open
USD 15,19
High
USD 15,64
Low
USD 15,07
Mkt. cap
2,02 mjd
Avg. vol.
2,10 m
Volume
2,36 m
52-wk high
USD 23,44
52-wk low
USD 11,41
EPS
-USD 0,69
Beta
1,91
Shares outstanding
130,92 m
No. of employees
16 k
News stories
From web sources and news partners
About Surgery Partners Inc
CEO-
Employees16 k
Founded2004
Headquarters-
SectorHealth care provider
Websitesurgerypartners.com
Analyst ratings
Based on 8 analysts giving stock ratings to SGRY in the past 3 months
Buy
Buy
5
Hold
3
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for SGRY in the last 3 months.
Highest
Current USD 15,40
USD 24,00 (+55,84%)
Average
USD 18,43 (+19,68%)
Lowest
USD 14,00 (-9,09%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andrew Mok CFA
Barclays
Hold
Maintained
USD 14,00
-9,1%
10/07/2026
Ben Hendrix
RBC Capital
Buy
Maintained
USD 19,00
+23,4%
09/29/2026
Joanna Gajuk
Bank of America Securities
Buy
Reiterated
USD 20,00
+29,9%
09/18/2026
Ryan Langston
TD Cowen
Buy
Reiterated
USD 19,00
+23,4%
09/18/2026
Benjamin Rossi
J.P. Morgan
Hold
Reiterated
USD 15,00
-2,6%
09/14/2026
Bill Sutherland
StoneX
Buy
Reiterated
USD 24,00
+55,8%
08/11/2026
Sarah James
Cantor Fitzgerald
Buy
Maintained
USD 18,00
+16,9%
08/10/2026
Matthew Gillmor CFA
KeyBanc
Hold
Maintained
-
-
08/11/2026
Gary Taylor
TD Cowen
Buy
Reiterated
USD 19,00
+23,4%
08/11/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
USD 19,00
+23,4%
07/13/2026
Brian Tanquilut
Jefferies
Buy
Maintained
USD 17,00
+10,4%
05/06/2026
A.J. Rice
UBS
Buy
Maintained
USD 21,00
+36,4%
03/10/2026
Last report
10 Aug. 2026
Fiscal period
Q2 2026
USD 0,10 / USD 0,06
+59,57%beat
Revenue / Est. (USD)
848,90 m / 830,32 m
+2,24%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
821,50 m
885,00 m
810,90 m
848,90 m
Cost of goods sold
626,20 m
672,80 m
650,70 m
658,70 m
Cost of revenue
626,20 m
672,80 m
650,70 m
658,70 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22,40 m
23,70 m
39,30 m
36,30 m
Operating expense
60,20 m
78,70 m
76,10 m
73,70 m
Total operating expenses
686,40 m
751,50 m
726,80 m
732,40 m
Operating income
135,10 m
133,50 m
84,10 m
116,50 m
Other non operating income
1,60 m
8,10 m
-
1,40 m
EBT including unusual items
30,80 m
42,60 m
-3,30 m
32,30 m
EBT excluding unusual items
65,40 m
72,50 m
19,10 m
53,10 m
Income tax expense
5,50 m
13,60 m
-1,20 m
2,60 m
Effective tax rate
17,86%
31,92%
36,36%
8,05%
Other operating expenses
-1,70 m
-4,90 m
-1,70 m
-1,90 m
Net income
-22,70 m
-15,00 m
-35,90 m
-15,00 m
Net profit margin
-2,76%
-1,69%
-4,43%
-1,77%
Earnings per share
0,13
0,12
-0,03
0,10
Interest and investment income
-
-
-
-
Interest expense
-76,50 m
-75,70 m
-69,10 m
-71,20 m
Net interest expenses
-76,50 m
-75,70 m
-69,10 m
-71,20 m
Depreciation and amortization charges
39,50 m
59,90 m
38,50 m
39,30 m
EBITDA
174,60 m
193,40 m
122,60 m
155,80 m
Gain or loss from assets sale
15,60 m
11,40 m
4,30 m
2,40 m
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme